Anzeige
Mehr »
Montag, 16.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
230 Leser
Artikel bewerten:
(0)

Emergent Health Corp. (OTC PINK:EMGE) Announces New Product Initiatives Related To Cancer Support, Stress Relief and Corona Virus Protection

KING OF PRUSSIA, PA / ACCESSWIRE / April 21, 2020 / The following are new initiatives being instituted by Emergent Health Corp. (OTC Pink:EMGE) (the "Company"):

1.The Company, through its direct and indirect subsidiaries, Emergent Medical Foods, Inc. and Emergent OTC Products, Inc. is in the process of designing NutraCan™ Nutritional Support and activating CancX® Nutritional Support to respective distribution channels.

Preliminary field testing of the products mentioned has appeared to indicate Cancer patients seem to obtain optimal nutrition. Among other goals, the products are designed to:

A. Help patients better tolerate treatment
B. Maintain strength and energy
C. Maximize quality of life

CancX® Nutrition Support is now also being marketed on Walmart.com which is second to Amazon in internet sales.

The Company is proud of these Cancer Support advances and expects even better health and financial results to develop over time.

2.The Company expects to introduce a new product to relieve stress. This product is patent pending. It is named Anxium™ Stress Relief. The scope and prevalence of distress and anxiety in modern society and the undesirable side effects of current treatments, the need for a natural non additive way to control and or eliminate the various forms of distress and anxiety is required and is imperative. Such an approach has been developed by the Company. It is expected to be released in the third quarter of 2020. The Company believes the potential for Anxium™ Stress Relief can help millions of citizens especially in these trying times. The Company expects profound financial results to follow.

3.The Company has begun negotiations to market what it believes can be the Rolls Royce of face masks. This patent pending advance involves the insertion of appropriate level UV light to kill any virus that for any reason penetrates the mask. This product is undergoing diligent laboratory testing and the developer is expected to submit it to the FDA for Medical Device approval. Such a negotiation upon its conclusion would be a major breakthrough for the Company advances in improving health care.

4.The Company continues to improve its network marketing capability of products that include adult stem cell nutrition as well as other health enhancing nutritional supplements.

5.The Company realizes it could need further capital to facilitate all of its objectives. For this reason, the Company expects to seek further capital before the end of 2020.

All of the above are forward looking statements.

Financials for the Company are being updated as of December 31, 2019. These financials are intended to be the foundation for updating at OTC Markets. The Company continues with no debt and sufficient operating capital.

Nothing in this press release has been reviewed by the Food & Drug Administration. The products mentioned are not intended to diagnose, treat, prevent or cure any disease.

This press release contains certain "forward-looking" statements, defined in the United States Private Securities Litigation Reform Act of 1995, that involve a number of risks and uncertainties. Statements, which are not historical facts, are forward-looking statements. The company, through its management, makes forward-looking public statements concerning its expected future operations, performance and other developments. Such forward-looking statements are estimates reflecting the company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. It is impossible to identify all such factors that could cause actual results to differ materially from those estimated by the company.

This press release is provided for information purposes only and is not intended to constitute an offer to sell or a solicitation of an offer to buy securities.

CONTACT:

Emergent Health Corp.
Investor Relations
484-518-9000

SOURCE: Emergent Health Corp.



View source version on accesswire.com:
https://www.accesswire.com/585953/Emergent-Health-Corp-OTC-PINKEMGE-Announces-New-Product-Initiatives-Related-To-Cancer-Support-Stress-Relief-and-Corona-Virus-Protection

© 2020 ACCESS Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.